The EU joint HTA procedure: a gate or barrier for access?
Pharmaceutical Technology
DECEMBER 22, 2022
As pharmaceutical companies launch their products across European countries, the joint procedure is intended to reduce the duplication of submissions with different evidence requirements and procedural times required at a country level, and thus streamline workflows and reduce administrative burden.
Let's personalize your content